We believe we have a strong basis for reversal on appeal based on the significant number of legal errors made during trial and in the charge to the jury." "Ms. Cappel-Coffey, who was morbidly obese, a strong candidate for using diet drugs and had a family history of cardiovascular disease prior to taking diet drugs, did not develop PPH symptoms until more than four years after she stopped using Pondimin," Mr. Sims continued. "There are no studies that demonstrate an association between Pondimin use and an increased risk of PPH that long after cessation of use." "The court's decision to preclude all mention of the risks of other diet drugs in this case will be a significant issue on appeal," Sims added.

The jury was not permitted to hear a wide range of evidence that raised questions about the cause of Ms. Cappel-Coffey's PPH and her willingness to take drugs that carried risks of injury or death in order to treat her morbid obesity.

For example, the court inappropriately excluded evidence that she used four other prescription diet drugs after she took Pondimin. Some of these drugs also include warnings about the risk of PPH in their product labeling. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies.

It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide.

The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.